Janux Therapeutics (JANX) News Today $59.61 -1.95 (-3.17%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Barclays PLC Purchases 144,883 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)Barclays PLC grew its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 496.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 174,061 shares of the company's stocDecember 18 at 4:16 AM | marketbeat.comJanux Therapeutics' (JANX) Overweight Rating Reaffirmed at Cantor FitzgeraldDecember 13, 2024 | americanbankingnews.com20,674 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Bought by Neo Ivy Capital ManagementNeo Ivy Capital Management bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,674 shares of the company'December 12, 2024 | marketbeat.comNavigating 10 Analyst Ratings For Janux TherapeuticsDecember 11, 2024 | benzinga.comBTIG Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)December 11, 2024 | markets.businessinsider.comCharles Schwab Investment Management Inc. Raises Position in Janux Therapeutics, Inc. (NASDAQ:JANX)Charles Schwab Investment Management Inc. boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 202.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 234,191 shares of the company's stock afterDecember 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Has $17.99 Million Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)Point72 Asset Management L.P. boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 190.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 395,875 shares of the company's stock after buying an additional 259,445December 7, 2024 | marketbeat.com13,500 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Bought by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 13,500 sharDecember 7, 2024 | marketbeat.comJanux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 MillionDecember 6, 2024 | businesswire.comScotiabank Reaffirms Their Hold Rating on Janux Therapeutics Inc (JANX)December 5, 2024 | markets.businessinsider.comTD Cowen Remains a Buy on Janux Therapeutics Inc (JANX)December 5, 2024 | markets.businessinsider.comJanux Therapeutics Inc (JANX) Receives a Buy from Stifel NicolausDecember 5, 2024 | markets.businessinsider.comSamsara BioCapital LLC Sells 22,526 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)Samsara BioCapital LLC trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 50.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,526 shares of the company's stock after sellingDecember 5, 2024 | marketbeat.comReadystate Asset Management LP Buys Shares of 32,335 Janux Therapeutics, Inc. (NASDAQ:JANX)Readystate Asset Management LP purchased a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 32,335 shares of the company's stockDecember 5, 2024 | marketbeat.comJanus Henderson Group PLC Increases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)Janus Henderson Group PLC boosted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 40.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,523,406 shares of the company's stock after purchasing an additional 721,563 shareDecember 5, 2024 | marketbeat.comJanux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsDecember 4, 2024 | businesswire.comWhy Janux Therapeutics Crushed the Market TodayDecember 4, 2024 | fool.comJanux Skyrockets: 69% Surge This Morning Leads to 650% Gain in a YearDecember 4, 2024 | finance.yahoo.comJanux Therapeutics (NASDAQ:JANX) Stock Quotes, Forecast and News SummaryDecember 4, 2024 | benzinga.comJanux Therapeutics Announces Proposed Public OfferingDecember 4, 2024 | finance.yahoo.comJanux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell Sells 15,000 SharesDecember 4, 2024 | insidertrades.comJanux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial ResultsDecember 3, 2024 | barrons.comJanux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: AnalystDecember 3, 2024 | benzinga.comJanux Therapeutics: Hype Breeds Volatility, And That Should Give You PauseDecember 3, 2024 | seekingalpha.comJanux Therapeutics Shares Soar Following Prostate Cancer Treatment ResultsDecember 2, 2024 | marketwatch.comJanux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPCDecember 2, 2024 | businesswire.comFmr LLC Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)Fmr LLC grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 0.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,824,675 shares of the company's stock after purchasing an additional 47,075 shares duringDecember 1, 2024 | marketbeat.comVestal Point Capital LP Has $22.03 Million Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)Vestal Point Capital LP reduced its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 33.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 485,000 shares of the company's stock afterNovember 29, 2024 | marketbeat.comAlgert Global LLC Makes New $1.11 Million Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)Algert Global LLC bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 24,472 shares of the company's stock, valued at approximately $1,112,000. A numbeNovember 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Takes $4.94 Million Position in Janux Therapeutics, Inc. (NASDAQ:JANX)Ally Bridge Group NY LLC acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 108,811 shares of the company's stock, valued at approximateNovember 28, 2024 | marketbeat.comInsider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells 25,000 Shares of StockNovember 28, 2024 | insidertrades.comVictory Capital Management Inc. Grows Position in Janux Therapeutics, Inc. (NASDAQ:JANX)Victory Capital Management Inc. grew its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 143.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,745 shares of the company's stock after bNovember 26, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Buy" by BrokeragesJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been assigned a consensus rating of "Buy" from the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, ten have assigned a buy recNovember 26, 2024 | marketbeat.comInnovative TRACTr Platform and Promising Prospects for Janux Therapeutics: An Analysis of JANX007’s Potential in Prostate Cancer TreatmentNovember 23, 2024 | markets.businessinsider.comLeerink Partners Initiates Coverage of Janux Therapeutics (JANX) with Outperform RecommendationNovember 23, 2024 | msn.comJanux Therapeutics (NASDAQ:JANX) Stock Rating Upgraded by Leerink PartnrsLeerink Partnrs upgraded Janux Therapeutics to a "strong-buy" rating in a research report on Friday.November 23, 2024 | marketbeat.comJanux Therapeutics initiated with an Outperform at LeerinkNovember 22, 2024 | msn.comJanux Therapeutics (NASDAQ:JANX) Coverage Initiated at Leerink PartnersLeerink Partners began coverage on shares of Janux Therapeutics in a research report on Friday. They set an "outperform" rating and a $79.00 price target on the stock.November 22, 2024 | marketbeat.comJanux Therapeutics’ Q3 Report: Financials and ProgressNovember 21, 2024 | markets.businessinsider.comJanux Therapeutics: Believable Theory, Strong Early Data, Needs ConfirmationNovember 19, 2024 | seekingalpha.comHC Wainwright Has Negative Outlook of JANX FY2024 EarningsJanux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Equities research analysts at HC Wainwright cut their FY2024 earnings estimates for Janux Therapeutics in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst S. Ramakanth now anticipates that theNovember 11, 2024 | marketbeat.comWilliam Blair Predicts Lower Earnings for Janux TherapeuticsJanux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - William Blair lowered their FY2024 EPS estimates for shares of Janux Therapeutics in a research note issued on Wednesday, November 6th. William Blair analyst M. Phipps now forecasts that the company will post earnings of ($1.28) per share forNovember 11, 2024 | marketbeat.comJanux Therapeutics Inc (JANX) Receives a Buy from Cantor FitzgeraldNovember 8, 2024 | markets.businessinsider.comPromising Phase I Trial Results and Tolerability Boost Buy Rating for Janux Therapeutics’ JANX007 in mCRPC TreatmentNovember 7, 2024 | markets.businessinsider.comJanux Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 6, 2024 | businesswire.comNisa Investment Advisors LLC Increases Position in Janux Therapeutics, Inc. (NASDAQ:JANX)Nisa Investment Advisors LLC lifted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 639.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 20,343 shares of the company's stock after buying an additional 17,592 shares durNovember 5, 2024 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading Up 6.3% - What's Next?Janux Therapeutics (NASDAQ:JANX) Trading Up 6.3% - Still a Buy?November 4, 2024 | marketbeat.comPromising Outlook for Janux Therapeutics Ahead of Key Phase 1 Data ReleaseNovember 1, 2024 | markets.businessinsider.comJanux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of "Moderate Buy" from BrokeragesJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued aNovember 1, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell Sells 25,000 SharesOctober 31, 2024 | insidertrades.com Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Forbes rich list released… #1 to be assassinated? (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now JANX Media Mentions By Week JANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JANX News Sentiment▼0.640.71▲Average Medical News Sentiment JANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JANX Articles This Week▼64▲JANX Articles Average Week Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RDY News Today SRPT News Today CTLT News Today PCVX News Today QGEN News Today ITCI News Today ROIV News Today ASND News Today RVMD News Today LNTH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JANX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
